A citation-based method for searching scientific literature

Fangdi Sun, Caroline E McCoach. Curr Treat Options Oncol 2021
Times Cited: 5







List of co-cited articles
14 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
97
60

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
276
60

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack,[...]. Ann Oncol 2020
83
60

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
75
40

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
Vivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, Daniel S W Tan, Dwight H Owen, Byoung Chul Cho, Herbert H Loong, Caroline E McCoach, Jared Weiss, Yu Jung Kim,[...]. Clin Cancer Res 2021
28
40

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021
29
40

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
224
40

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Alexander Drilon, Jessica J Lin, Thomas Filleron, Ai Ni, Julie Milia, Isabella Bergagnini, Vaios Hatzoglou, Vamsidhar Velcheti, Michael Offin, Bob Li,[...]. J Thorac Oncol 2018
83
40

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Toyoaki Hida, Vamsidhar Velcheti, Karen L Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E Dutcus, Min Ren, Tomohide Tamura. Lung Cancer 2019
53
40

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M S Hashemi, Florian Huemer, Anders Vikström,[...]. Ther Adv Med Oncol 2021
10
40

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
507
40

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
219
40

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Lisa M Hess, Yimei Han, Yajun Emily Zhu, Naleen Raj Bhandari, Anthony Sireci. BMC Cancer 2021
14
40

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
215
40

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
17
20

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
Anne Marie Lennon, Adam H Buchanan, Isaac Kinde, Andrew Warren, Ashley Honushefsky, Ariella T Cohain, David H Ledbetter, Fred Sanfilippo, Kathleen Sheridan, Dillenia Rosica,[...]. Science 2020
204
20


Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Tommy Nyberg, Debra Frost, Daniel Barrowdale, D Gareth Evans, Elizabeth Bancroft, Julian Adlard, Munaza Ahmed, Julian Barwell, Angela F Brady, Carole Brewer,[...]. Eur Urol 2020
82
20

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Lola-Jade Palmieri, Laurent Mineur, David Tougeron, Benoît Rousseau, Victoire Granger, Jean-Marc Gornet, Denis Smith, Astrid Lievre, Marie-Pierre Galais, Solene Doat,[...]. Oncologist 2020
3
33

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Julien Taieb, Andreas Jung, Andrea Sartore-Bianchi, Marc Peeters, Jenny Seligmann, Aziz Zaanan, Peter Burdon, Clara Montagut, Pierre Laurent-Puig. Drugs 2019
38
20

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
Sergey V Silkin, Sergey S Startsev, Marina E Krasnova, Grigory A Raskin, Natalia V Mitiushkina, Aglaya G Iyevleva, Anna P Sokolenko, Evgeny N Imyanitov. J Gastrointest Cancer 2016
10
20

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
227
20

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
277
20

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
168
20

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
20


Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
574
20

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Rafael G Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky,[...]. J Clin Oncol 2008
20

The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.
Anja Irmisch, Ximena Bonilla, Stéphane Chevrier, Kjong-Van Lehmann, Franziska Singer, Nora C Toussaint, Cinzia Esposito, Julien Mena, Emanuela S Milani, Ruben Casanova,[...]. Cancer Cell 2021
31
20

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Jacob J Adashek, Vivek Subbiah, Razelle Kurzrock. Trends Cancer 2021
35
20

HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
Astrid De Cuyper, Marc Van Den Eynde, Jean-Pascal Machiels. Clin Colorectal Cancer 2020
16
20

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
541
20

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Aglaya G Iyevleva, Natalia V Mitiushkina, Nina A Karaseva, Sergey V Orlov, Larisa N Volodina, Yulia E Kulikova, Alexandra M Lozhkina, Alexandr O Ivantsov, Vladislav I Tiurin, Alexandr V Togo,[...]. J Thorac Oncol 2014
11
20


EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Jordi Remon, Lizza E L Hendriks, Andres F Cardona, Benjamin Besse. Cancer Treat Rev 2020
50
20

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
118
20

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta,[...]. Eur Urol 2020
10
20

Microsatellite instability in colorectal cancer-the stable evidence.
Eduardo Vilar, Stephen B Gruber. Nat Rev Clin Oncol 2010
519
20

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W Prager, Richard Greil, Alexander Stein,[...]. Lancet Oncol 2020
156
20

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.
Esther Conde, Federico Rojo, Javier Gómez, Ana Belén Enguita, Ihab Abdulkader, Ana González, Dolores Lozano, Nuria Mancheño, Clara Salas, Marta Salido,[...]. J Clin Pathol 2022
12
20

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, Raanan Berger, David I Quinn, Matthew D Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean-Pierre Delord,[...]. Cancer Discov 2018
160
20

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock. Cancer Cell 2021
183
20

Spectrum of APC and MUTYH germ-line mutations in Russian patients with colorectal malignancies.
G A Yanus, T A Akhapkina, A O Ivantsov, E V Preobrazhenskaya, S N Aleksakhina, I V Bizin, A P Sokolenko, N V Mitiushkina, E Sh Kuligina, E N Suspitsin,[...]. Clin Genet 2018
11
20

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, Timothy J Price, Gerald S Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barlesi,[...]. N Engl J Med 2021
349
20

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
308
20

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.
Sergey V Orlov, Magaripa A Urtenova, Maria A Sviridenko, Denis V Nesterov, Tatiana N Sokolova, Evgeny N Imyanitov. Case Rep Oncol 2020
5
20

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
20


Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Miguel Garcia-Pardo, Laura Ortega, María Jesús Fernández-Aceñero, Pilar García Alfonso, Miguel Martín, Andrés J Muñoz. J Gastrointest Cancer 2021
2
50

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Kenta Takahashi, Eri Ishibashi, Toshio Kubo, Yohei Harada, Hideyuki Hayashi, Masayuki Kano, Yasushi Shimizu, Hidekazu Shirota, Yukiko Mori, Manabu Muto,[...]. Medicine (Baltimore) 2020
6
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.